Complement Therapeutics is a spin-out from The University of Manchester that focuses on developing treatments for Complement-related diseases, particularly age-related macular degeneration. The company conducts translational research to gain insights into the Complement System and its dysregulation in macular degeneration.

Complement Therapeutics

Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

BioGeneration Ventures

Forbion Capital Partners

Panakes Partners

Seroba Life Sciences

Gimv

Hadean Ventures

Cambridge Innovation Capital

Wow! Our team was featured on the big screen in Times Square NYC! Thanks Nasdaq for celebrating this milestone with us! 🎉
 
Even Mo'Nique (Netflix) put on a big smile when she saw the announcement.

#nasdaq #SeriesA #funding #biotech #timesquare #nyc #team

🌟 Exciting News! 🌟
 
The June Edition of BioProcess International has published a new article featuring Pamela Whalley, Associate Director CMC, on the topic  presented at Advanced Therapies in Miami, earlier this year: Partnering for Gene Therapy Manufacturing - What is the Key to Success?
 
In this insightful piece, Pam explores the crucial factors that gene therapy developers must consider when selecting a CDMO (Contract Development and Manufacturing Organization) and highlights the importance of demanding a pilot study to ensure success.
 
Read the full article here: https://lnkd.in/gynu-mnA
 
#GeneTherapy #Biotech #CDMO #Pharmaceuticals #BioProcess #ManufacturingSuccess #HealthcareInnovation #BPI #CMC #complement #conference

Excited to be on the panel today to discuss CMC Best Practices at Oxford Global Gene Therapy Development2024 conference.

OxfordGlobal Conferences UK 
Complement Therapeutics

The Cell and Gene Therapy Catapult (CGT Catapult), Touchlight, and Complement Therapeutics, today announce that they have been awarded over £1 million in a grant from Innovate UK.

During this two-year project, Touchlight, the CGT Catapult and Complement Therapeutics will combine their expertise in #GeneTherapy development and manufacturing to develop an innovative recombinant adeno-associated virus (rAAV) production process.

Learn more: https://buff.ly/4b9xzYL 

#AdvancedTherapies #ATMPs #Manufacturing #Innovation

📣 It’s #conference season! Our Director of Biomarker and Bioanalysis, Rachel Green will be a guest speaker at this year’s Workshops on Recent Issues in Bioanalysis conference in Texas, USA. Rachel will be presenting on our novel complement precision medicine platform (CPM) on May 9th, so don’t miss out!
 
Find the event’s agenda here: https://lnkd.in/gzvSY7HQ
 
#WRIB #WRIB2024 #research #ophthalmologyresearch #guestspeaker #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #texas #nonclinical #bioanalysis #biomarker #novel #platform

📣 Exciting news! The non-clinical data from our lead asset, CTx001, has been approved for showcasing in a poster format at this year's American Society of Gene & Cell Therapy (ASGCT) on May 10th.
 
Our CTO, Matthias Hebben and VP Operations, Mustafa Munye will be attending the conference, so don't miss the opportunity to speak with them! 
 
#asgct #asgct2024 #research #ophthalmologyresearch #posterpresentation #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #baltimore #nonclinical

📣 With the American Society of Gene & Cell Therapy (ASGCT) approaching on May 7-11th, don’t miss out on our CTO, Matthias Hebben discussing AAV manufacturing platforms to successfully support clinical development at 10:20 AM in Ballroom 3.  
 
Find the event’s agenda here: https://lnkd.in/gSjPsVn

#asgct #asgct2024 #research #ophthalmologyresearch #aav #manufacturing #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #baltimore #nonclinical #cmc #AAVmanufacturing #conferences #guestspeaker

📢 The non-clinical data from our lead programme, CTx001, has been accepted for a poster presentation at Association for Research in Vision and Ophthalmology (ARVO) 2024. 

Our team, including Rafiq Hasan, Dennis Keefe, and parisa zamiri will be attending, so make sure to drop them a message! 
 
#arvo #arvo2024 #research #ophthalmologyresearch #posterpresentation #complement #biotechnology #ophthalmology #geographicatrophy #AMD #genetherapy #seattle #nonclinical

🌟  The full Complement team had an absolute blast at our recent team building day at the TEWIN BURY FARM LIMITED!
 
We kicked off the day with a diversity of thought workshop 📒 where we had the chance to explore each other's backgrounds, experiences, and perspectives. This session proved to be invaluable, fostering understanding, empathy, and unity within our team 🤝.
 
We also engaged in thrilling activities designed to test our skills and strengthen teamwork. Axe throwing 🎯 brought out our competitive spirits, while archery 🏹 and laser clay shooting 🎇 put our precision and focus to the test.

Happy (early) Easter 🐣 from Complement Therapeutics !

#TeamBuilding #DiversityandInclusion #happyeaster #ComplementTherapeutics #teambonding #easter #team #complement

We are excited to welcome Kathryn Parsley, MPhil, Ph.D, to our team as Vice President, Regulatory Affairs! 🎊

Kathryn holds an MPhil in Microbiology/Immunology and a PhD in Molecular Immunology/gene therapy. She began her career in anthrax vaccine research at CAMR, UK, then spent 12 years at the Institute of Child Health and Great Ormond Street Hospital NHS Trust, UK, managing gene and cell-based Phase I/II clinical trials. She transitioned to PPD as a Senior Regulatory Affairs Manager, specializing in global Phase I-IV studies, gene therapy, and GMO products. Kathryn later joined Boyd Consultants and Gyroscope Therapeutics before moving to Novartis. She also contributes to ATMP education and recently co-authored an article on EU Clinical Trials Regulation and European GMO legislation for TOPRA Regulatory Rapporteur.

#WelcomeAboard #GeneTherapy #ophthalmology #ComplementBiology #team #JobOpening #JoinUs

COMP

COM:COMPLEMENTTX

Complement Therapeutics

name

homepage url

country

linkedin url

sector

industry

Description

peer of

investor of

Metrics